Gemina Laboratories Ltd. reported earnings results for the full year ended January 31, 2023. For the full year, the company reported net loss was CAD 5.98 million compared to CAD 4.73 million a year ago. Basic loss per share from continuing operations was CAD 0.1 compared to CAD 0.1 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.47 CAD | 0.00% | -6.00% | -12.96% |
Apr. 02 | Gemina Laboratories Sign First Strategic License Agreement | CI |
Mar. 18 | Gemina Laboratories Ltd. announced that it has received CAD 0.91 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
-12.96% | 25.41M | |
-6.26% | 12.1B | |
-3.93% | 8.16B | |
+7.10% | 5.78B | |
+30.16% | 5.59B | |
-7.47% | 4.23B | |
-57.20% | 2.87B | |
+12.56% | 2.71B | |
-4.67% | 2.35B | |
+27.38% | 2.21B |
- Stock Market
- Equities
- GLAB Stock
- News Gemina Laboratories Ltd.
- Gemina Laboratories Ltd. Reports Earnings Results for the Full Year Ended January 31, 2023